Imagion Biosystems has announced Appendix 4D and Half Year Results H1 2020. These are the highlights: Significant advancements towards initiating first-in-human study, on track to
Imagion Biosystems Limited gives notice that, on 18 August 2020 the Company issued 21,633,200 fully paid ordinary shares (Shares) in the Company as the result
Imagion Biosystems Limited announce that it has received $1.29m for the exercise of unlisted options issued under the terms of the 2018 Rights Issue outlined
Imagion Biosystems has announced the following Change of Director’s Interest Notices. Read them at ASX: Robert Proulx Michael Harsh Mark Van Asten Jovanka Naumoska Dianne
Imagion Biosystems has announced Appendix 3G — FY20 Director’s Options. Download the announcement.
Imagion Biosystems has announced Appendix 3G — FY20 Performance Rights and Performance Options. Download the announcement.
Imagion Biosystems is pleased to provide an update with regard to its plans to undertake a Phase I study of its first MagSense® product for
Imagion Biosystems Limited announces Appendix 2A — IBXOA Options. Read the announcement.
Imagion Biosystems Limited announces Appendix 2A — Fully Paid Ordinary Shares. Read the announcement.
Imagion Biosystems Limited announces the proposed issue of 1,500,000 options expiring 28 April, 2023. Read the announcement.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance